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1. Introduction 
Serotonin (5-hydroxytryptamine, 5-HT) was isolated and characterized during the late 1930s 
through the 1950s. Since then, serotonin has been shown to play a key role in a range of 
behaviors and processes, including sensory gating and processing, behavioral inhibition, 
appetite, aggression, sleep, mood, and neuroendocrine secretion (Anderson, 2005). The 
serotonin neuron system stretches abundant branches from a limited number of cells in the 
brain stem and widely and densely projects the brain (Takeuchi, 1988). Therefore, the 
serotonin neuron system is considered to be “the total control system”. During development 
of the brain, the serotonin neuron system is not only essential for formation and 
maintenance of synapses (Lauder, 1990), but also is affected by a variety of environmental 
factors. These findings are crucial for understanding the pathogenesis of many 
developmental disorders. This paper reviews the involvement of the serotonin neuron 
system in neurotransmission in autism spectrum disorders.  
2. Anatomical characteristics of the serotonin neuron system 
The distribution of the serotonin neuron system overwhelms that of other neuron systems 
(Nieuwenhuys, 1985; Takeuchi, 1988). The serotonin neuron system is a slow synaptic 
potential system with a long time lapse, similar to the physiology of noradrenalin and 
dopamine neuron systems. In this review, we examine the central nervous system (CNS) in 
monkeys (macaca fuscata) describing the anatomical characteristics of the serotonin neuron 
system, in order to understand the diversity of functions of serotonin in the brain and the 
pathogenesis of developmental disorders.  
2.1 Cell bodies of serotonin neurons are localized in the brain stem 
The cell bodies of serotonin neurons are localized from the caudal part of the midbrain red 
nucleus to the decussation of the pyramid of the medulla. This pattern is similar among 
species. Approximately 65% of the cell bodies are localized near the raphe nuclei group at 
the center of the brain stem, including the dorsal raphe nucleus (B7), superior central 
nucleus (B8), pontine raphe nucleus (B5), raphe magnus nucleus (B3), obscurus raphe 
nucleus (B2), and raphe pallidus nucleus (B1) from the rostral side, while the remaining cell 
bodies are localized at other sites. Serotonin neurons number between 25-50,000 in rodents 
and >150,000 in primates (monkeys), and the B7 group accounts for a large proportion of the 
serotonin neurons (Nieuwenhuys, 1985; Takeuchi, 1988).  
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2.2 Serotonin fiber distribution  
Axons and dendrites of serotonin neurons are distributed more densely and widely than 
previously predicted in the central nervous system. The density and area of their 
distribution exceed those of the noradrenalin neuron system. The distribution of 
serotonergic axons and dendrites differs markedly between species. This tendency is most 
remarkable in the neocortex. The distribution pattern of serotonin fibers in the motor, 
sensory, and visual cortices of rodents is similar, whereas it differs markedly in the 
neocortex in primates. These distribution patterns of serotonin fibers are presumed to be 
dependent on the functions of the neocortex. In general, serotonin fibers are distributed 
more densely in the granular cell layer in the input system of the cortices than in the 
pyramidal cell layer in the output system, and the density of serotonin distribution is much 
higher in the primary visual cortex than in the primary motor cortex in primates. On the 
other hand, noradrenalin fibers are distributed more densely in the pyramidal cell layer in 
the output system and the distribution is complementary to that of serotonin fibers, i.e. 
“mutually exclusive distribution pattern” (Nieuwenhuys, 1985; Takeuchi, 1988).   
2.3 Projections to other monoamine neuron systems 
The serotonin neuron system regulates the activity of other monoamine neurons, in 
particular, dopamine neurons. For example, serotonin fibers are distributed in a markedly 
high density in the substantia nigra, and synapses are formed with a number of dopamine 
neurons in the substantia nigra in all animal species. Thus, the serotonin neuron system 
controls dopamine neurons in the substantia nigra at the cell body level via the 5-HT2A 
receptor. Serotonin fibers are distributed not only at sites rich in dopamine fiber endings, 
such as the striatum and nucleus accumbens, but also in the prefrontal area of the frontal 
cortex, which is important for the pathogenesis of developmental disorders. 
2.4 High sprouting capability 
The serotonin neuron system exhibits a markedly high sprouting capability compared with 
that of other neuron systems. In general, serotonin fibers are sparsely distributed at the 
striatum. When the substantia nigra is chemically ablated unilaterally during development (by 
12 days after birth in mice) using 6-hydroxydopamine, dopamine neurons in the substantia 
nigra and dopamine fibers in the striatum disappear. In contrast, axon sprouting of serotonin 
fibers appears in the striatum of the experimental animals and generates a markedly dense 
distribution. These findings suggest that the serotonin neuron system has a strong influence on 
the dopamine neuron system (Yamazoe, 2001). This phenomenon, called “heterotypic 
sprouting”, is observed particularly between the serotonin neuron and dopamine neuron 
systems. Heterotypic sprouting of serotonin fibers during development is thought to be 
involved in the plasticity of the brain and the modification of symptoms of diseases derived 
from dysfunction of the dopamine neuron system. Therefore, heterotypic sprouting is 
particularly intriguing in investigating the pathogenesis of developmental disorders.  
2.5 Volume transmission 
As mentioned previously, the serotonin neuron system is called the total control system or 
the diffuse projection system, and plays a major role in central nervous system function. The 
conventional projection system is called the “wiring transmission” system, and the serotonin 
neuron system is thought to be responsible for non-functional (“volume transmission”) and 
junctional neurotransmission (Bunin, 1999). 
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2.6 Development and the serotonin neuron system 
During brain development, serotonin has been shown to influence the maturation of target 
tissues, including dendritic elaboration, synaptogenesis, neurogenesis and organization of 
the cortex (Lauder, 1978, 1990; Kondoh, 2004). At early stages of development, when the 
blood–brain barrier is not yet fully formed, serotonin can enter the brain of a developing 
fetus, and cause a loss of serotonin terminals through negative feedback. This loss of 
serotonin innervation persists throughout subsequent development and the symptoms of 
autism appear (Whitaker-Azmitia, 2005). 
Serotonin neurons appear at 5 weeks of gestation and their numbers increase dramatically 
through the tenth week. Raphe nuclei can be detected at 15 weeks gestation. Axons from 
serotonin neurons grow into the cortex prenatally and expression of the serotonin 
transporter begins at the end of the first trimester. Serotonin levels in the brain increase 
postnatally for 2-5 years, then decline to adult levels at approximately 50% of the peak 
values (Whitaker-Azmitia, 2005). 
In rats, serotonin fibers exhibit a temporary control over the primary sensory cortex during 
fetal days 2-14, which corresponds to the period of synapse formation. Serotonin 
transporters appear temporarily in glutamatergic thalamocortical afferent nerve fibers 
within 2 weeks after birth in rats. Serotonin concentrations that are too high or too low 
influence normal development during this period (Erzurumlu & Kind, 2001). An insufficient 
concentration of serotonin in the brain during synapse formation interferes with the 
development of the barrel in the rat somatosensory area. In contrast, excessive serotonin 
induces superabundant axonal branching in the somatosensory area and obscures the 
boundary of the barrel, as observed in monoamine oxydase A-knockout mice (Erzurumlu & 
Kind, 2001). Abnormalities in synaptic connection induced by a reduced or excess 
intracerebral serotonin concentration greatly reduces the number of dendrites not only in 
the sensory cortex, but also in the hippocampus. Considering that serotonin fibers are 
densely distributed in the granular cell layer in the cerebral neocortex, polymorphisms of 
the serotonin transporter gene reported in autism spectrum disorders patients may 
influence serotonin regulation in the thalamocortical nerve pathway, which may lead to 
abnormalities in sensory and cognitive functions in most autism spectrum disorders 
patients.  
Development of the serotonin neuron system is influenced by a variety of environmental 
factors. In mice, studies have shown that malnutrition and hypoxia during the neonatal 
period induce irreversible changes in the serotonin neuron system, that vulnerability of the 
serotonin neuron system is dependent on the region, and that a variety of environmental 
factors may induce brain injury associated with the serotonin neuron system (Ishimura, 
1989). Moreover, the serotonin neuron system is influenced greatly by aging, and S100β in 
astrocytes is involved in the dynamics of serotonin fibers in the hippocampus. Axons 
originating from the B7 and B8 groups show different intracerebral distribution and 
degenerative process associated with aging, and each has specific neurobiological 
significance (Nishimura, 1995). Considering the pathogenesis of autism spectrum disorders, 
it is of interest that the serotonergic system is activated through rhythmic movements, such 
as gait, chewing and respiration, and that adequate physical activity is important for 
serotonin activation (Kohyama, 2011). Thus, accumulating evidence indicates that 
serotonergic projections undergo continuous age-related change through early childhood 
and that the serotonin neuron system is particularly plastic and fragile. 
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3. Serotonergic neurotransmission in autism spectrum disorders 
In this review, autistic disorder (Kanner's ‘autism’), childhood disintegrative disorder, 
pervasive development disorder not otherwise specified (‘atypical autism’), and Asperger 
syndrome are collectively termed autism spectrum disorders (Persico & Bourgeron, 2006). 
According to previous studies, abnormalities in the brain stem-subcortical structure 
(caudate nucleus, putamen, and pallidum)-cerebellum network, as well as in the 
hippocampus, piriform gyrus, and cingulate gyrus, play a central role in the pathogenesis. A 
number of studies have examined the relationship between autism spectrum disorders and 
abnormalities in the serotonin neuron system, and these abnormalities are considered to be 
the core of the pathogenesis of autism spectrum disorders (Johnston & Blue, 2006; Persico & 
Bourgeron, 2006). 
3.1 Hyperserotonemia 
Increased blood serotonin concentrations in approximately 30% of autism spectrum disorders 
patients strongly suggests that serotonin is involved with the onset of autism spectrum 
disorders. Although an increase in serotonin uptake by platelets elevates serotonin 
concentrations in the blood, an abnormality in the serotonin neuron system has not been 
identified in these patients. The relationship of blood serotonin to the behavioral aspects of 
autism spectrum disorders and the range of blood serotonin concentrations in the autism 
spectrum disorders group are not clear. Serotonin levels have not been correlated consistently 
with degree of mental retardation or other symptoms (Anderson, 2005). High serotonin levels 
in the blood have been suggested to cause a low intracerebral serotonin concentration in 
autism spectrum disorders, and are considered to be the result of negative feedback on 
serotonin neurons (Whitaker-Azmitia, 2005). This negative feedback is likely mediated by the 
5-HT1A, which is the earliest appearing serotonin receptor and has a prenatal peak both in 
human and rodents. In some cases, the receptor appears transiently during development in 
brain regions, such as the cerebellum, that do not express the receptor in the adult.  
Although most serotonin-related neurochemical research in autism spectrum disorders has 
focused on hyperserotonemia, several studies examining serotonin in cerebrospinal fluid have 
been reported (Anderson, 2005). However, cerebrospinal fluid studies are in general agreement 
that little or no difference exists between the mean levels of the major serotonin metabolite, 5-
hydroxyindoleacetic acid in autism spectrum disorders patients and control groups. 
3.2 Serotonin hypothesis based on clinical viewpoints  
The concept of autism has changed over time. The main symptoms of autism spectrum 
disorders include onset in early infancy, male predominance, age-dependent symptomatic 
development, and symptomatic vulnerability to the influence of environmental factors. The 
neuronal system responsible for these clinical distinctions should have the following 
characteristics: development in early infancy, predominant vulnerability in males, 
involvement in the regulation of the growth and function of the brain by projecting to the 
subcortical to cortical levels, and susceptibility to environmental factors. These features 
suggest that a brainstem monoamine neuron system may be the primary contributor to the 
pathogenesis of autism spectrum disorders. Among them, the serotonin neuron system is 
considered the most favored candidate since it fulfills all of the characteristics outlined 
above (Segawa & Nomura 2005). Abnormalities in the serotonin neuron system are thought 
to cause disturbances in the sleep/arousal rhythm observed from the early stages of autism 
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spectrum disorders, poor social skills, adaptation disorder to a new environment, and 
impaired cognitive function. 
3.3 Positron emission tomography studies 
Analysis of serotonin metabolism by positron emission tomography (PET) revealed that 
serotonin synthesis is disturbed in the frontal lobe, thalamus, and cerebellum, which are 
thought to be involved in the pathogenesis of autism spectrum disorders. PET using α [C-11] 
methyl-L-tryptophan showed that the uptake of α [C-11] methyl-L-tryptophan in autism 
spectrum disorders is different between the right and left sides in the frontal lobe, thalamus, 
and cerebellar dentate nucleus. When compared with the adult levels of serotonin synthesis 
in the whole brain, the level of serotonin synthesis in children up to five years old without 
autism spectrum disorders was >200% that of adults, and gradually decreased thereafter to 
the level in adults. The serotonin synthesis levels decreased earlier in female children than 
in male children. However, in children with autism spectrum disorders, serotonin synthesis 
gradually increased from 2 to 15 years old to a level 1.5-fold that of the adult (Chugani, 1999; 
Chugani, 2002). PET studies using [11C](+)McN5652, which is highly selective for the 
serotonin transporter, as a tracer showed that serotonin transporter density in Asperger 
syndrome patients was significantly decreased in a wide area containing the midbrain, basal 
ganglia, and cerebral cortex. These results need to be verified fully.  
3.4 Neuropathologic changes implicating the serotonin neuron system 
Most regions of the brain reported to be responsible for autism receive rich projections from 
the serotonin neuron system pathologically, in that they have dense serotonergic terminals. 
Thus, abnormalities in serotonin neurotransmission may be involved in the pathogenesis of 
autism spectrum disorders. To date, potential foci responsible for autism spectrum disorders 
have been reported, including the superior and inferior olivary nuclei, facial nerve nucleus, 
dorsal raphe nucleus in the brain stem, the frontal lobe (prefrontal area) and lateral lobe 
(superior temporal gyrus) in the cerebral cortex, cerebellar vermis and hemispheres, and the 
cingulate gyrus, septal area, amygdala, and hippocampus in the cerebral limbic system 
(Amaral, 2008). Neuropathologic foci of autism spectrum disorders are present widely, 
suggesting that brain injury occurs at an early stage of development.  
In regards to neurotransmission, most of the foci reported to be responsible of autism 
spectrum disorders are strongly projected by the serotonin neuron system, except for the 
cerebellum. A particularly strong rationale has been developed for involvement of the 
amygdala and associated areas of the limbic cortex. More specifically, the core social 
relatedness deficits in autism spectrum disorders serve to focus attention on the rostral 
limbic system, including the amygdala, septum, medial orbitofrontal cortex, anterior insular 
cortex, anterior cinglate cortex, and the nucleus accumbens (Anderson, 2005). The various 
limbic areas are richly innervated with serotonergic projections, and the nucleus accumbens, 
an area crucial in appetitive and reward processes, has an especially dense serotonergic 
innervation. Meanwhile, in the cerebellum, where serotonin fiber density is lower than in 
most other brain areas, the serotonin neuron system is thought to be crucial for cerebellar 
function. As described before, 5HT-1A receptors have a rich and early expression in the 
rodent and human cerebellum. Therefore, neuropathological findings strongly suggest that 
abnormalities in serotonergic neurotransmission may be involved in the pathogenesis of 
autism spectrum disorders. Furthermore, neuropathological findings in the brain were 
compared between reeler mice deficient in reelin and autism spectrum disorders patients, 
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and common lesion distribution and microscopic findings between the two conditions were 
observed (Persico & Bourgeron, 2006). In addition, the serotonin agonist, 5-
methoxytryptamine, influences the level of reelin, which shows an abnormal level in the 
brains of autism spectrum disorders patients. 
3.5 Animal models of autism spectrum disorders  
In animals, serotonin is involved in mediating behaviors of sleep, arousal, aggression, 
impulsivity, and affiliation, all of which are relevant to autism. Reduced serotonergic 
function has been associated with worsened sleep, depressed mood, altered arousal, 
increased aggression, and increased impulsivity (Anderson, 2005). In general, serotonin 
plays an inhibitory role in the brain. Its actions are complex and depend greatly on the 
specific location or distribution of serotonergic terminals and classes of receptors stimulated. 
In regards to animal models for autism spectrum disorders, a thalidomide-administered 
model (rat), a valproic acid-administered model (rat), a Borna disease virus infection model 
(rat), an amygdala injury model (monkey, rat), and a hypothyroidism model (rat) have been 
constructed. A majority of the animal models show abnormal early development of the 
serotonin neuron system, although abnormalities in the dopamine and noradrenalin neuron 
systems have also been suggested. Furthermore, as in the autism spectrum disorders animal 
models, oxytocin-deficient and oxytocin receptor-deficient mice have been reported.  
3.6 Other models related to serotonin 
The involvement of the serotonin neuron system in the pathogenesis of autism spectrum 
disorders has been reported from a variety of fields. (1) A mutation in the tryptophan 2,3-
dioxygenase gene that encodes the rate-limiting enzyme in tryptophan-serotonin-kynurenine 
metabolism was reported in autism spectrum disorders patients. (2) Serotonin depletion 
during the neonatal period increased the thickness of the cerebral cortex, which is a common 
finding with an increased cerebral volume in autism spectrum disorders patients. (3) 5-
methoxytryptamine has been shown to influence the level of reelin, which shows an abnormal 
level in the brain in autism spectrum disorders patients (Janusonis, 2004). (4) A selective 
serotonin reuptake inhibitor was shown to improve clinical symptoms. However, the factors 
that may critically affect the response to selective serotonin reuptake inhibitor treatment and 
adverse effects in individuals with autism spectrum disorders need to be clarified. (5) 
Risperidone, another frequently used medication for patients with autism spectrum disorders, 
is an atypical neuroleptic that acts as a potent antagonist at the 5-HT2A receptor.  
3.7 Oxytocin and autism spectrum disorders 
Oxytocin is a peptide hormone produced by neurosecretory cells at the hypothalamus 
supraoptic nucleus and paraventricular nucleus in mothers and it is secreted from the 
posterior pituitary lobe. The hormone exhibits a variety of functions in the brain, as well as 
roles in delivery and galactopoiesis. Oxytocin regulates emotion in the company of 
somebody and oxytocin concentrations in the blood are low in autism spectrum disorders 
patients, therefore, the hormone attracts the most attention in investigations of the 
pathogenesis of autism spectrum disorders (Kirsch. et al; 2005). Oxytocin plays a role in 
signal transmission between the mother and the fetus so that neurons in the fetus are 
prepared for delivery. Oxytocin temporarily switches intracerebral GABAergic 
neurotransmission from the excitatory to inhibitory state in the fetus at delivery and exerts 
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neuroprotective action. Serotonin fiber endings are abundant on oxytocin neurons at the 
hypothalamus supraoptic nucleus and paraventricular nucleus, and it should be noted that 
oxytocin neurons are regulated by the serotonin neuron system.  
Studies to date show that prenatal treatment with a serotonin agonist, 5-methoxytryptame, 
results in “autistic-like” behaviors such as decreased social bonding, sensory hyper-
responsiveness, seizures and motor changes  (Whitaker-Azmitia, 2005). 5-methoxytryptame 
(serotonin agonist)-treated animals have a loss of oxytocin-containing cells in the 
hypothalamus, as well as an apparent loss of oxytocin projections towards other brain 
regions such as the amygdala and the supraoptic nucleus. The amygdala is of interest in 
autism spectrum disorders because there have been reported changes in volume, cell-
packing density and function in this region. In addition, the central nucleus of the amygdala 
receives an intense serotonergic innervation from the dorsal raphe nucleus, which may 
modulate behavioral responses to fear (Adolphs, 2002). 
3.8 Glutamic acid, neuroligin, and neurexin in autism spectrum disorders 
Glutamic acid, as well as serotonin plays an important role in the development of the brain. 
Glutamic acid is essential for the development and plasticity of the cerebral cortex, and is 
responsible for the collaborative function with serotonin in the development of the thalamo-
cortical pathway. In the cerebellum in autism spectrum disorders patients, up regulation of 
the glutamate receptor 1 subunit of AMPA mRNA has been reported. In addition, genetic 
mutations in neuroligin-3 and 4 genes result in changes in glutamatergic synapses. 
Furthermore, as it has been shown that the balance between excitatory and inhibitory 
neurotransmission is disturbed by the down-regulation of neuroligin-1, shifting to the 
excitatory side. Synapse dynamics such as plasticity, production, and pruning is impaired; 
therefore, the importance of glutamic acid in autism spectrum disorders has been suggested 
(Johnston & Blue, 2006). Neuroligin and neurexin are cell adhesion molecules located at the 
postsynaptic and presynaptic region, respectively. They promote synapse formation 
bidirectionally in the glutamatergic nerve system and GABAergic nerve system, and they 
have been called “the bridge between molecules and the mind” (Dean & Dresbach, 2006). 
Insufficient inhibitory neurotransmission is related to impaired cognitive processes, physical 
control, and the tendency to be complicated with abnormal brain waves and epilepsy in 
autism spectrum disorders. While mutated proteins of neuroligin 3, neuroligin 4, and 
neurexin 1 have been reported in autism spectrum disorders patients, the involvement of 
neuroligin 4 in attention-deficit hyperactivity disorder and learning disorder has also been 
suggested (Dean & Dresbach, 2006; Betancur, 2009). 
3.9 Autism spectrum disorders-related proteins 
Autism spectrum disorders-related proteins have a variety of functions including 
remodeling of chromatin and transcription regulation, the actin cell cytoskeleton, the 
induction and maintenance of dendritic spines, neurotransmission (neurotransmitters, 
receptors, and transporters), as a second messenger, apoptosis, cell adhesion, and nerve cell 
mobilization (Persico & Bourgeron, 2006). SLC6A4, which encodes the serotonin transporter, 
has been intensively investigated as an autism spectrum disorders-related gene. In addition, 
genes encoding a GABA receptor subunit (GABAR: GABRA4 and GABRB1), an NMDA 
receptor subunit (GRIN2A), the oxytocin receptor (OCTR), and the vasopressin receptor 
(AVPR1) have also been investigated as autism spectrum disorders-related.  
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4. Serotonergic neurotransmission in attention deficit hyperactivity disorder 
symptoms in patients with autism spectrum disorders 
The majority of the patients with autism spectrum disorders are diagnosed as having 
attention deficit hyperactivity disorder at an early stage of the disease, suggesting a 
common neuronal dysfunction between attention deficit hyperactivity disorder and autism 
spectrum disorders. Attention deficit hyperactivity disorder is a disease that involves a 
number of genetic factors. It is a heterogeneous disorder with a wide variation in symptoms 
among individuals, and is influenced by environmental factors. Dysfunction in the 
catecholaminergic (dopaminergic and noradrenergic) system in the neocortex (prefrontal 
area)-subcortical structure (the caudate nucleus, putamen, pallidum, and thalamus)-
cerebellum pathway is the core of the pathogenesis of attention deficit hyperactivity 
disorder. The serotonin neuron system is related not only with the abnormality in the 
catecholaminergic system, but also directly with the pathogenesis of attention deficit 
hyperactivity disorder (Biederman, 2005). 
4.1 Dopaminergic neurotransmission in attention deficit hyperactivity disorder 
It is generally accepted that abnormalities in the dopaminergic system are the core of the 
pathogenesis of attention deficit hyperactivity disorder. Among monoamines, dopamine is 
located profusely in the brain. The dopaminergic system is also considered a diffuse 
projection system, however, the distribution is relatively localized compared with the 
serotonergic and noradrenergic systems. The cell bodies of the dopamine neuron system are 
distributed in a concentrated manner at the midbrain substantia nigra pars compacta and 
ventral tegmental area. Dopamine neurons are also localized in the mesocorticolimbic 
dopaminergic pathway, which has projections to the ventral tegmental area, accumbens 
nucleus, amygdala, septal area, olfactory tubercule, and prefrontal area, and is deeply 
involved in functions such as motivation, sustained attention, cognitive function, and 
reward behavior (Björklund & Dunnett 2007).  
A dopamine transporter, localized at the cell membrane, plays an important role in 
dopamine metabolism by incorporating extracellular dopamine into the cell and decreasing 
extracellular dopamine concentrations. Single photon emission computed tomography with 
the administration of altropane, which binds the dopamine transporter specifically, showed 
that the binding capacity of 123I altropane in the striatum increased by 70% in adults with 
attention deficit hyperactivity disorder, suggesting the over expression of the dopamine 
transporter in attention deficit hyperactivity disorder.  
After methylphenidate was administered for 4 weeks in the treatment for attention deficit 
hyperactivity disorder adults, single photon emission computed tomography showed that 
dopamine transporter activity in the striatum, which was higher than that in the control 
group before treatment, decreased after treatment and showed no significant difference 
from controls. The normalization of dopaminergic neurotransmission confirmed the clinical 
effect of methylphenidate. Furthermore, positron emission tomography with C11altropanea 
was carried out for a comparative experiment that took into account a history of medication 
and smoking, and the results showed that the dopamine transporter was significantly 
increased at the caudate nucleus (on the right) in adult attention deficit hyperactivity 
disorder cases. Therefore, deregulation of the dopamine transporter resulted in attention 
deficit hyperactivity disorder (Spencer, 2007). These findings are consistent with the 
hypothesis that the striatum is involved in the regulation of complicated cognitive function 
and that the putamen is involved mostly in the control of physical function.  
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The over-expression of the dopamine transporter in the striatum in humans was confirmed 
by a number of studies using single photon emission computed tomography and positron 
emission tomography, but examinations of a bilateral difference of the dopamine 
transporter in the striatum are not consistent. The distribution of the dopamine transporter 
is greatly dependent on site, and distribution density is much higher in the striatum than in 
the frontal lobe, which is known to have the dopaminergic system at the highest density in 
the cerebral cortex (Stahl, 2008).  
As described previously, the monoamine system is responsible for not only conventional 
neurotransmission via synapses, but also volume transmission without the involvement of 
synapses. Dopamine carries out neurotransmission in a wide area in the prefrontal area by 
spreading to the outside of synapses, as well as synaptic clefts, and it is involved in frontal 
cortex functions, such as selective attention at the dorsal anterior cingulate gyrus, sustained 
attention in the dorsal lateral prefrontal area, regulation of hyperkinesias in the premotor 
cortex, and impulsivity control in the orbitofrontal cortex. 
4.2 Serotonergic neurotransmission in attention deficit hyperactivity disorder 
4.2.1 Interaction between dopaminergic and serotonergic systems 
Previous studies of the dopaminergic system in the mesocorticolimbic pathway in attention 
deficit hyperactivity disorder model rats have demonstrated a loss of function in 6-
hydroxydopamine rats, a loss of function and gain of function in spontaneously 
hypertensive rats, and a gain of function in dopamine transporter knockout/knock-down 
mice. The anatomical characteristics of the serotonin neuron system suggest a mechanism 
for disinhibition of the dopaminergic system in association with loss of function in the 
serotonergic system. Therefore, it is highly likely that abnormalities not only in the 
dopaminergic system, but also in the serotonergic system are involved in the pathogenesis 
of attention deficit hyperactivity disorder.  
When 6-hydroxydopamine is administered to neonatal rats, they show hyperkinesias for a 
specific period after birth. In this model, 6-hydroxydopamine destroyed dopaminergic fibers 
in the prefrontal area and striatum, and dysfunction of the dopaminergic system or the 
ensuing dopamine receptor hypersensitivity is considered the underlying mechanism for 
hyperkinesias. Serotonin fiber density is increased remarkably in the striatum of these 6-
hydroxydopamine model rats and mice. It has been reported that the excessive control of 
the serotonergic system is involved in the inhibition of hyperkinesias by a central nervous 
system stimulant. The delicate balance between the dopaminergic and serotonergic systems 
is thought to be necessary for normal behavior and monoamines are likely involved in 
heterogeneity (sub-classification) of attention deficit hyperactivity disorder. In general, 
when this disorder in the dopaminergic system is predominant, destructive and aggressive 
behavior is less frequent, and hyperkinesias and attention deficit are the chief complaints of 
attention deficit hyperactivity disorder. However, when impairment in the serotonergic 
system is predominant, not only hyperkinesias and attention deficit, but also destructive 
and aggressive behavior are observed in attention deficit hyperactivity disorder.  
4.2.2 Direct involvement of the serotonergic system in attention deficit hyperactivity 
disorder  
Dopamine transporter knockout mice are known as an attention deficit hyperactivity 
disorder animal model. The administration of methylphenidate alleviates the hyperkinesias 
in dopamine transporter knockout mice. However, since dopamine transporter, a target of 
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methylphenidate, is deficient in this mouse model, it is reasonable to conclude that the effect 
is exerted via other neuron systems. When a serotonin transporter inhibitor (a selective 
serotonin reuptake inhibitor) is administered in this mouse model, hyperkinesias are 
alleviated despite no change in extracellular dopamine concentrations (Gainetdinov, 1999). 
On the other hand, when a selective noradrenalin transporter inhibitor (a selective 
noradrenalin reuptake inhibitor) is administered, hyperkinesias are not alleviated, which 
suggests that serotonergic neurotransmission is involved in the functional mechanism of 
methylphenidate for the improvement in attention deficit hyperactivity disorder symptoms.    
The serotonergic system per se is directly involved in attention deficit hyperactivity disorder 
and is involved mostly in sustained attention, particularly in the dorsal lateral prefrontal area. 
Recently, serotonin at the dorsal striatum and prefrontal area has been suggested to play an 
important role in inhibiting impulsivity in decision-making and aggressiveness (Doya, 2008).  
Selective serotonin reuptake inhibitors improve attention deficit hyperactivity disorder 
symptoms via the 5-HT1A, 5-HT2A, and 5-HT2C receptors. Since 5-HT1B receptor-deficient 
mice show hyperkinesias and aggressiveness, the 5-HT1B receptor has attracted attention as 
a genetic factor of attention deficit hyperactivity disorder, and the relationship between the 
subtypes of attention deficit hyperactivity disorder and the attention deficit-predominant 
type has also been examined (Smoller, 2006).  
5. Conclusions 
Serotonin is the earliest developing neurotransmitter system in the mammalian brain, and 
eventually becomes the mostly widely distributed system in the brain, contacting most cells 
of the cortex. Thus, the serotonin neuron system develops early enough, and is sufficiently 
widespread that it can influence maturation of many other regions in the brain. The 
serotonin neuron system that develops at the early stage has a core influence on neural 
development, morphogenesis, and synapse formation and maintenance. The control of the 
serotonin neuron system over other monoamine neurons, in particular, dopamine neurons, 
has been demonstrated. These neuroanatomical findings are important for understanding 
the pathogenesis of developmental disorders. 
In autism spectrum disorders, abnormalities in the brain stem-subcortical structure (caudate 
nucleus, putamen, and pallidum)-cerebellum network, as well as the hippocampus, piriform 
gyrus, and cingulate gyrus, plays a central role in the pathogenesis. Since most parts of the 
brain that have been reported to be responsible for autism spectrum disorders strongly 
receive projections from the serotonin neuron system, dysfunction of serotonergic 
neurotransmission is considered to be the core of the pathogenesis of autism spectrum 
disorders. Abnormalities in the serotonergic system are thought to cause disturbances in the 
sleep/arousal rhythm observed from the early stages of autism spectrum disorders, poor 
social skills, and adaptation disorder to a new environment. Dysfunction in the 
dopaminergic and noradrenergic systems in the neocortex-subcortical structure-cerebellum 
pathway is the core of the pathogenesis of attention deficit hyperactivity disorder, and the 
serotonin neuron system is related not only with the abnormality in the catecholaminergic 
system, but also directly with the pathogenesis of attention deficit hyperactivity disorder.  
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